Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
At the annual meeting of the American Association of Cancer Researchers, presenters discuss strategies to improve the safety and effectiveness of reengineered T cells in eradicating tumors. Via Krishan Maggon 
Scoop.it!
The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for further advancements to facilitate and broaden their applicability. One potentially beneficial innovation is to exploit new T cell sources that reduce the need for autologous cell manufacturing and enable cell transfer across histocompatibility barriers. Here we review emerging T cell engineering approaches that utilize alternative T cell sources, which include virus-specific or T cell receptor-less allogeneic T cells, expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T lymphocytes. The latter offer the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products. Via Krishan Maggon
Krishan Maggon 's curator insight,
April 13, 2015 5:49 AM
Volume 16, Issue 4, 2 April 2015, Pages 357–366 3601|| Perspective New Cell Sources for T Cell Engineering and Adoptive ImmunotherapyMaria Themeli1, Isabelle Rivière1, Michel Sadelain1, , doi:10.1016/j.stem.2015.03.011
Scoop.it!
Abstract The recent successes of adoptive T-cell immunotherapy for the treatment of hematologic malignancies have highlighted the need for manufacturing processes that are robust and scalable for product commercialization. Here we review some of the more outstanding issues surrounding commercial scale manufacturing of personalized-adoptive T-cell medicinal products. These include closed system operations, improving process robustness and simplifying work flows, reducing labor intensity by implementing process automation, scalability and cost, as well as appropriate testing and tracking of products, all while maintaining strict adherence to Current Good Manufacturing Practices and regulatory guidelines. A decentralized manufacturing model is proposed, where in the future patients’ cells could be processed at the point-of-care in the hospital. Via Krishan Maggon
Gilbert C FAURE's insight:
OPEN
Krishan Maggon 's curator insight,
March 14, 2015 1:39 PM
Cancer Gene Therapy (2015) 22, 72–78; doi:10.1038/cgt.2014.78; published online 23 January 2015 Towards a commercial process for the manufacture of genetically modified T cells for therapyOPEN A D Kaiser1, M Assenmacher1, B Schröder1, M Meyer1, R Orentas2, U Bethke1and B Dropulic2 1Miltenyi Biotec GmbH, Bergisch Gladbach, Germany2Lentigen Technology Inc., Gaithersburg, MD, USACorrespondence: Dr A Kaiser, Miltenyi Biotec GmbH, Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany. E-mail: andrewk@miltenyibiotec.de; B Dropulic, Lentigen Technology Inc., 910 Clopper Road, Gaithersburg, MD, USA. E-mail: boro.dropulic@lentigen.com Received 22 October 2014; Accepted 5 November 2014 |
Scoop.it!
The MaxCyte GT® Flow Transfection System is a universal platform technology for rapid, automated loading of CAR (chimeric antigen receptor) mRNA into peripheral blood mononuclear cells using closed-system aseptic processing. Via Krishan Maggon
Krishan Maggon 's curator insight,
April 22, 2015 2:17 AM
Press Release:: MaxCyte and Johns Hopkins University Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies
Scoop.it!
Highlights Via Krishan Maggon
Krishan Maggon 's curator insight,
March 18, 2015 5:44 AM
Trends in Immunology Volume 36, Issue 2, February 2015, Pages 71–80 Review Targeting T cell metabolism for therapyDavid O'Sullivan, Erika L. Pearce doi:10.1016/j.it.2014.12.004 |
CAR T Cell immunotherapy, TIL, ATC, TCR unpredictable toxicity at AACR 2015